Press release
Alzheimer’s Drug PRI-002 Receives EMA Approval for Phase II Trial
The Alzheimer’s drug candidate PRI-002 is entering the next clinical trial phase: the European Medicines Agency (EMA) has granted approval to conduct a phase II clinical trial. This is the first time that the drug candidate will be tested on a larger number of Alzheimer’s patients. The drug was developed at Forschungszentrum Jülich and Heinrich Heine University Düsseldorf (HHU).